ErbB-2 protein in sera and tumors of breast cancer patients

Breast Cancer Research and Treatment

Volumn 49, Issue 3, 1998, Pages 261-270

  Breuer, Brenda ^a,b,g   Smith, Steven ^c   Thor, Ann ^d   Edgerton, Susan ^d   Osborne, Michael P ^a,b   Minick, Richard ^b   Cody III, Hiram S ^b,f   Nowak, Eugene ^b   Cortese, Armand ^b   Simmons, Rache M ^a,b   Carney, Walter P ^e   Brandt Rauf, Paul W ^c  

^a STRANG CANCER PREVENTION CENTER   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d EVANSTON HOSPITAL   (United States)

^e Oncogene Science   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g Jewish Home and Hospital   (United States)

Author keywords

Age; erbB 2 protein; Nulliparity; Serum; Tumor

Indexed keywords

ONCOPROTEIN;

AGE; ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST CARCINOMA; CANCER INVASION; CHILDBIRTH; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; NULLIPARA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SERODIAGNOSIS; STATISTICAL ANALYSIS; TUMOR VOLUME;

AGE FACTORS; BREAST NEOPLASMS; FEMALE; HUMANS; MENARCHE; MENOPAUSE; PARITY; RECEPTOR, ERBB-2; RISK FACTORS; SMOKING; STATISTICS, NONPARAMETRIC;

EID: 7344257734     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006033214721     Document Type: Article

References (33)

1. Chen Y, Dong J, Lu Y, McGee JO: Quantitative detection of amplification of proto-oncogenes in breast cancer. Chin Med J Engl 108: 849-854, 1995
2. Tang CK, Perez C, Grunt T, Waibel C, Cho C, Lupu R: Involvement of heregulin-beta2 in the acquisition of the hormone-independent phenotype of breast cancer cells. Cancer Res 56: 3350-3358, 1996
3. Narita T, Funahashi H, Satoh Y, Takagi H: C-erbB-2 protein in the sera of breast cancer patients. Breast Cancer Res Treat 24: 97-102, 1992
4. Tiwari RK, Borgen PI, Wong GY, Cordon-Cardo C, Osborne MP: HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis. Anticancer Res 12: 419-426, 1992
5. Leitzel K, Teramoto Y, Sampson E, Mauceri J, Langton BC, Demers L et al.: Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. J Clin Oncol 10: 1436-1443, 1992
6. Hosono M, Saga T, Sakahara H, Kobayashi H, Shirato M, Endo K et al.: Construction of immunoradiometric assay for circulating erbB-2 protooncogene product in advanced breast cancer patients. Jpn J Cancer Res 84: 147-152, 1993
7. Breuer B, De Vivo I, Luo JC, Smith S, Pincus MR, Tutum AH et al.: erbB-2 and myc oncoproteins in sera and tumors of breast cancer patients. Cancer Epidemiol. Biomarkers & Prev 3: 63-66, 1994
8. Breuer B, Smith S, Osborne MP, Simmons RM, Carney WP, Brandt-Rauf PW: ErbB-2 protein levels in healthy, asymptomatic women. Biomarkers 1: 141-143, 1996
9. Carney WP, Hamer PJ, Petit D, Retos C, Greene R, Zabrecky JR et al.: Detection and quantitation of the human neu oncoprotein. J Tumor Marker Oncol 6: 53-72, 1991
10. Luo JC, Yu MW, Chen CJ, Santella RM, Carney WP, Brandt-Rauf PW: Serum c-erbB-2 oncopeptide in hepatocellular carcinogenesis. Med Sci Res 21: 305-307, 1993
11. Cohen J: Statistical Power Analysis for the Behavioral Sciences: second edition. Hillsdale, New Jersey, Lawrence Erlbaum Associates, 1988
12. SAS Institute Inc. SAS/STAT User's Guide, version 6, fourth editon, Cary, NC. SAS. Instil. Inc. 1989
13. Kandl H, Seymour L, Bezwoda WR: Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer. Br J Cancer 70: 739-742, 1994
14. Perera FP, Hemminki K, Gryzbowska E, Motykiewicz G, Michalska J, Santella RM et al.: Molecular and genetic damage in humans from environmental pollution in Poland. Nature 360: 256-258, 1992
15. Leitzel K, Teramoto Y, Sampson EL, Wallingford A, Weaver S, Deniers L et al.: Elevated c-erbB-2 levels in the serum and tumor extracts of breast cancer patients. Proc AACR 32: 167, 1991
16. Breuer B, Luo JC, DeVivo I, Pincus M, Tatum AH, Daucher J et al.: Detection of elevated c-erbB-2 oncoprotein in the serum and tissue in breast cancer. Mod Sci Res 21: 383-384, 1993
17. Isola JJ, Holli K, Oksa H, Teramoto Y, Kallioniemi OP: Elevated erbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer. Cancer 73: 652-658, 1994
18. Leitzel K, Teramoto Y, Konrad K, Chinchilli VM, Volas G, Grossberg H et al.: Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 13: 1129-1135, 1995
19. Kynast B, Binder L, Marx D, Zoll B, Schmoll H-J, Oellerich M et al.: Determination of a fragment of the c-erb-2 translation product p185 in serum of breast cancer patients. Can Res Clin Oncol 119: 249-252, 1993
20. Varley JM, Swallow JE, Brammar WJ, Whiltaker JL, Walker RA: Alterations to either c-erbB-2 (neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. Oncogene 1: 423-430, 1987
21. Watanabe N, Miyamoto M, Tokuda Y, Kubota M, Ando Y, Tajima T et al.: Serum c-erbB-2 in breast cancer patients. Acta Oncol 33: 901-904, 1994
22. Chu SY, Lee NC, Wingo PA, Senie RT, Greenberg RS, Peterson HB: The relationship between body mass and breast cancer among women enrolled in the Cancer and Steroid Hormone Study. J Clin Epidemiol 44: 1197-1206, 1991
23. Hsieh CC, Trichopoulos D, Katsouyanni K, Yuasa S: Age at monarchic, age at menopause, height and obesity as risk factors for breast cancer: associations and interactions in an international case-control study. Int J Cancer 46: 796-800, 1990
24. de Waard F, Trichopoulos D: A unifying concept of the actiology of breast cancer. Int J Cancer 41: 666-669, 1988
25. Le Marchand L, Kolonel LN, Earle ME, Mi MP: Body size at different periods of life and breast cancer risk. Am J Epidemiol 128: 137-152, 1988
26. Yong LC, Brown CC, Schatzkin A, Schairer C: Prospective study of relative weight and risk of breast cancer: the Breast Cancer Detection Demonstration Project follow-up study, 1979 to 1987-1989. Am J Epidemiol 143: 985-995, 1996
27. Gail M, Brinton L, Byar D, Corle D, Green S, Schairer C et al.: Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81: 1879-1886, 1989
28. De Bortoli M, Maggiora P, Capello D, Antoniotti S, Saviozzi S, Sapei ML et al.: Hormonal control of growth factor receptor expression. Ann NY Acad Sci 784: 336-348, 1996
29. Antoniotti S,Taverna D, Maggiora P, Sapei ML, Hynes NE, De Bortoli M: Oestrogen and epidermal growth factor down-regulate erbB-2 oncogene protein expression in breast cancer cells by different mechanisms. Br J Cancer 70: 1095-1101, 1994
30. Lodato RF, Maguire HC Jr., Greene MI, Weiner DB, LiVolsi VA: Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Mod Pathol 3: 449-454, 1990
31. Poller DN, Silverstein MJ, Galea M, Locker AP, Elston CW, Blarney RW et al.: Ductal carcinoma in situ of the breast: A proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression. Mod Pathol 7: 257-262, 1994
32. Barnes DM: e-erbB-2 amplification in mammary carcinoma. J Cell Biochem 17G: 132-138, 1993
33. Lampe B, Genz T, Maaben V, Mikorey S, Klosterhalfen T: Correlation of e-erbB-2 protein expression with histologic grade, lymph node involvement and steroid receptor status in human breast tumors. Arch Gynecol Obstet 251: 45-50, 1992